Voyager Therapeutics ROE 2014-2022 | VYGR
Current and historical return on equity (ROE) values for Voyager Therapeutics (VYGR) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Voyager Therapeutics ROE - Return on Equity Historical Data |
| Date |
TTM Net Income |
Shareholder's Equity |
Return on Equity |
| 2022-03-31 |
$-0.07B |
$0.08B |
-75.88% |
| 2021-12-31 |
$-0.07B |
$0.10B |
-66.20% |
| 2021-09-30 |
$-0.09B |
$0.09B |
-76.23% |
| 2021-06-30 |
$0.02B |
$0.11B |
12.70% |
| 2021-03-31 |
$0.04B |
$0.14B |
29.27% |
| 2020-12-31 |
$0.04B |
$0.15B |
31.03% |
| 2020-09-30 |
$0.04B |
$0.17B |
37.83% |
| 2020-06-30 |
$-0.06B |
$0.08B |
-66.85% |
| 2020-03-31 |
$-0.04B |
$0.08B |
-40.39% |
| 2019-12-31 |
$-0.04B |
$0.10B |
-41.22% |
| 2019-09-30 |
$-0.05B |
$0.11B |
-57.91% |
| 2019-06-30 |
$-0.06B |
$0.12B |
-71.30% |
| 2019-03-31 |
$-0.10B |
$0.10B |
-130.17% |
| 2018-12-31 |
$-0.09B |
$0.05B |
-121.92% |
| 2018-09-30 |
$-0.08B |
$0.07B |
-82.11% |
| 2018-06-30 |
$-0.08B |
$0.08B |
-81.20% |
| 2018-03-31 |
$-0.07B |
$0.10B |
-70.14% |
| 2017-12-31 |
$-0.07B |
$0.13B |
-63.53% |
| 2017-09-30 |
$-0.07B |
$0.09B |
-65.92% |
| 2017-06-30 |
$-0.06B |
$0.11B |
-46.78% |
| 2017-03-31 |
$-0.05B |
$0.12B |
-35.46% |
| 2016-12-31 |
$-0.04B |
$0.14B |
-26.45% |
| 2016-09-30 |
$-0.03B |
$0.15B |
-21.32% |
| 2016-06-30 |
$-0.03B |
$0.16B |
-21.66% |
| 2016-03-31 |
$-0.03B |
$0.16B |
-27.59% |
| 2015-12-31 |
$-0.04B |
$0.17B |
-57.56% |
| 2015-09-30 |
$-0.04B |
$0.10B |
-135.92% |
| 2015-06-30 |
$-0.03B |
$0.00B |
-12800.00% |
| 2015-03-31 |
$-0.03B |
$0.00B |
-12000.00% |
| 2014-12-31 |
$-0.02B |
$0.00B |
-6800.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.227B |
$0.037B |
|
Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.
|
